Complete COVID Validated Solutions

MGI is providing a high throughput, clinically validated workflow to address major bottlenecks for large-scale COVID-19 testing. The solution includes BGI's Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2, as well as MGI's MGIEasy Nucleic Acid Extraction Kit, MGISP-960RS Automated Sample Preparation System, in addition to, MGISTP-7000 Robotic Sample Accessioning Workhorse.  

BGI's highly-sensitive RT-PCR testing kit, which can return results within three hours, detects the RNA of SARS-CoV-2 extracted from a wide range of respiratory samples. The kit is validated on a number of RT-PCR instruments with broad adaptability. It features 

1. High sensitivity: Limit of detection as low as 100 viral copies/mL
2. High specificity: No cross-reactivity with 54 human respiratory pathogens
3. Ease of use: All-inclusive with pre-mixed reaction reagents
4. Easy interpretation: Analysis of one target with well-defined controls

The authorization includes MGI's MGIEasy Nucleic Acid Extraction Kit as a validated method for viral RNA extraction, which is currently in abundant supply worldwide and addresses a severe sample preparation bottleneck for widespread testing. In addition, MGI's robotic sample preparation system significantly improves throughput and reproducibility. The combination of the MGI products enable processing of 192 samples in 80 minutes, a major increase in productivity compared to manual processing.